肝癌肝移植新进展——2019年ILTS年会速递

汪国营

doi:10.3969/j.issn.1674-7445.2020.01.007

肝癌肝移植新进展——2019年ILTS年会速递

doi: 10.3969/j.issn.1674-7445.2020.01.007

汪国营

510630 广州，中山大学附属第三医院肝脏外科暨肝移植中心（Email：wanggy3@126.com）

基金项目:

国家“十三五”科技重大专项 2017ZX10203205-006-001

国家“十三五”科技重大专项 2017ZX10203205-001-003

详细信息

作者简介:
汪国营，主任医师，博士研究生导师，中山大学附属第三医院肝脏外科暨肝移植中心主任助理。兼任中国医师协会器官移植医师分会青年委员会副主任委员及移植管理学组委员、中国研究型医院学会普外青年委员会副主任委员、广东省医学会微创外科学分会委员及肝癌分会委员。兼任《Translational Cancer Research》、《器官移植》、《中华肝脏外科手术学电子杂志》等杂志编委。入选首届树兰卓越青年医学人才、首批广东省杰出青年医学人才。承担国家自然科学基金2项以及省市级科研项目多项，以第一作者或通讯作者发表SCI及核心期刊论文50余篇，参编专著及本科生规划教材5部。获广东省科技进步一等奖（R5）及国际肝移植协会青年研究者奖等奖励6次

中图分类号: R617, R735.7
计量
- 文章访问数: 244
- HTML全文浏览量: 139
- PDF下载量: 26
- 被引次数: 0
出版历程
- 收稿日期: 2019-11-03
- 网络出版日期: 2021-01-19
- 刊出日期: 2020-01-15

New progress on liver transplantation for liver cancer: 2019 ILTS annual collection

Wang Guoying

Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

摘要

摘要: 国际肝移植协会（ILTS）第25届年会于2019年5月15~18日在加拿大多伦多市召开。本文针对肝癌肝移植专题，从肝移植术前降期和桥接治疗、肝移植术后肝癌复发的预测、个体化免疫抑制方案、肝移植术后肝癌复发的防治等方面进行归纳和总结，并对近两年相关进展的国内外文献进行综述。
- 肝移植 /
- 肝癌 /
- 国际肝移植协会(ILTS) /
- 降期治疗 /
- 桥接治疗 /
- 复发 /
- 免疫抑制方案
Abstract: The 25th Annual Congress of International Liver Transplantation Society (ILTS) was held from May 15 to 18, 2019 in Toronto, Canada. Focusing on the special topic of liver transplantation for liver cancer, down-staging liver cancer and bridging therapy before liver transplantation, prediction of liver cancer recurrence after liver transplantation, individualized immunosuppressive scheme, prevention and treatment of liver cancer recurrence after liver transplantation were summarized in this article. In addition, the literatures published in recent two years related to the research progress were reviewed.
- Liver transplantation /
- Liver cancer /
- International Liver Transplantation Society (ILTS) /
- Down-staging treatment /
- Bridging therapy /
- Recurrence /
- Immunosuppressive regimen

HTML全文

参考文献(33)

[1]	HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1):358-380. DOI: 10.1002/hep.29086.
[2]	EILARD MS, ANDERSSON M, NAREDI P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1):568. DOI: 10.1186/s12885-019-5760-8.
[3]	HALAZUN KJ, NAJJAR M, ABDELMESSIH RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new moral to the story[J]. Ann Surg, 2017, 265(3):557-564. DOI: 10.1097/SLA.0000000000001966.
[4]	LAI Q, VITALE A, IESARI S, et al. The intention-to-treat effect of bridging treatments in the setting of Milan criteria-in patients waiting for liver transplantation[J]. Liver Transpl, 2019, 25(7):1023-1033. DOI: 10.1002/lt.25492.
[5]	MAGGIORE U, PASCUAL J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients[J]. Adv Chronic Kidney Dis, 2016, 23(5):312-316. DOI: 10.1053/j.ackd.2016.08.002.
[6]	NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2019, DOI: 10.1111/ajt.15617 [Epubahead of print].
[7]	KHALAILEH A, KHOURY T, HARKROSH S, et al. Multiplication product of model for end-stage liver disease and donor risk index as predictive models of survival after liver transplantation[J]. Eur J Gastroenterol Hepatol, 2019, 31(9):1116-1120. DOI: 10.1097/MEG.0000000000001396.
[8]	MEHTA N, HEIMBACH J, HARNOIS DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncol, 2017, 3(4):493-500. DOI: 10.1001/jamaoncol.2016.5116.
[9]	MAZZAFERRO V, SPOSITO C, ZHOU J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma[J]. Gastroenterology, 2018, 154(1):128-139. DOI: 10.1053/j.gastro.2017.09.025.
[10]	中国医师协会器官移植医师分会, 中华医学会器官移植学分会.中国肝癌肝移植临床实践指南(2018版) [J/CD].中华移植杂志(电子版), 2018, 12(4):145-150. DOI: 10.3877/cma.j.issn.1674-3903.2018.04.001. Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physician of Chinese Medical Doctor Association. Clinical practice guideline for liver transplantation of liver cancer in China [J/CD]. Chin J Transplant(Electr Vers), 2018, 12(4):145-150. DOI: 10.3877/cma.j.issn.1674-3903.2018.04.001.
[11]	GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with Meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10):1260-1273. DOI: 10.1111/apt.15253.
[12]	RODRÍGUEZ-PERÁLVAREZ M, GUERRERO M, BARRERA L, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplantation, 2018, 102(12):2056-2064. DOI: 10.1097/TP.0000000000002270.
[13]	JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7):932-945. DOI: 10.1002/lt.25191.
[14]	IAVARONE M, INVERNIZZI F, CZAUDERNA C, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation[J]. Am J Transplant, 2019, 19(11):3176-3184. DOI: 10.1111/ajt.15551.
[15]	LIPSON EJ, BAGNASCO SM, MOORE J JR, et al. Tumor regression and allograft rejection after administration of anti-PD-1[J]. N Engl J Med, 2016, 374(9):896-898. DOI: 10.1056/NEJMc1509268.
[16]	汪国营, 唐晖, 张英才, 等.程序性死亡受体(PD)-1单克隆抗体治疗肝癌肝移植术后复发诱发急性免疫性肝炎:附1例报告[J].器官移植, 2016, 7(1):44-47. DOI: 10.3969/j.issn.1674-7445.2016.01.008. WANG GY, TANG H, ZHANG YC, et al. Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report[J]. Organ Transplant, 2016, 7(1):44-47. DOI: 10.3969/j.issn.1674-7445.2016.01.008.
[17]	FISHER J, ZEITOUNI N, FAN W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J]. J Am Acad Dermatol, 2019, DOI: 10.1016/j.jaad.2019.07.005[Epubahead of print].
[18]	ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1):106. DOI: 10.1186/s40425-019-0585-1.
[19]	DE BRUYN P, VAN GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?[J]. Curr Opin Oncol, 2019, 31(2):54-64. DOI: 10.1097/CCO.0000000000000505.
[20]	HO CM, CHEN HL, HU RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11: 1758835919843463. DOI: 10.1177/1758835919843463.
[21]	MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7):970-973. DOI: 10.1177/2050640618774631.
[22]	DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6):1054-1062. DOI: 10.21037/jgo.2018.07.05.
[23]	RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet?[J]. Hepatology, 2018, 67(3):1166-1168. DOI: 10.1002/hep.29575.
[24]	CHEN JA, ESTEGHAMAT N, KIM EJ, et al. PD-1 blockade in a liver transplant recipient with microsatellite unstable metastatic colorectal cancer and hepatic impairment[J]. J Natl Compr Canc Netw, 2019, 17(9):1026-1030. DOI: 10.6004/jnccn.2019.7328.
[25]	BIONDANI P, DE MARTIN E, SAMUEL D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient[J]. Ann Oncol, 2018, 29(1):286-287. DOI: 10.1093/annonc/mdx548.
[26]	MEHTA N, DODGE JL, GRAB JD, et al. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time[J]. Hepatology, 2019, DOI: 10.1002/hep.30879 [Epubahead of print].
[27]	VERNA EC, PATEL YA, AGGARWAL A, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant[J]. Am J Transplant, 2019, DOI: 10.1111/ajt.15697[Epubahead of print].
[28]	KORNBERG A, WITT U, SCHERNHAMMER M, et al. The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma[J]. J Surg Oncol, 2019, 120(7):1126-1136. DOI: 10.1002/jso.25721.
[29]	MCVEY JC, SASAKI K, FIRL DJ, et al. Prognostication of inflammatory cells in liver transplantation: is the waitlist neutrophil-to-lymphocyte ratio really predictive of tumor biology?[J]. Clin Transplant, 2019, 26:e13743. DOI: 10.1111/ctr.13743.
[30]	GRĄT K, PACHO R, GRĄT M, et al. Impact of body composition on the risk of hepatocellular carcinoma recurrence after liver transplantation[J]. J Clin Med, 2019, 8(10): E1672. DOI: 10.3390/jcm8101672.
[31]	COSTENTIN CE, BABABEKOV YJ, ZHU AX, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation?[J]. Hepatology, 2019, 69(3):1324-1336. DOI: 10.1002/hep.30278.
[32]	HONG SK, LEE KW, YOON KC, et al. Different prognostic factors and strategies for early and late recurrence after adult living donor liver transplantation for hepatocellular carcinoma[J]. Clin Transplant, 2019, 33(10):e13703. DOI: 10.1111/ctr.13703.
[33]	ZHUANG L, MOU HB, YU LF, et al. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2019, DOI: 10.1016/j.hbpd.2019.09.011[Epubahead of print].